MAG and chronic inflammatory demyelinating polyradiculoneuropathy: According to the 2021 EAN/PNS criteria, patients with positive anti-MAG antibodies are excluded from a diagnosis of CIDP, which precludes them from receiving CIDP-specific treatments or participating in related clinical trials [3▪].